Comparison of hepatocellular carcinoma in Eastern versus Western populations

  title={Comparison of hepatocellular carcinoma in Eastern versus Western populations},
  author={Su Pin Choo and Wan Ling Tan and Brian Kim Poh Goh and Wai Meng Tai and Andrew X. Zhu},
Hepatocellular carcinoma (HCC) is a heterogeneous disease that remains highly prevalent in many Asian countries and is the second most common cause of cancer‐related mortality worldwide. Significant differences exist between Eastern and Western populations on many key aspects of HCC, contributing to the potential different treatment outcomes and challenges of clinical trial design and data interpretation. In this review, the authors compare HCC in Asia versus the West and highlight 1… 
Shifting Epidemiology of Hepatocellular Carcinoma in Far Eastern and Southeast Asian Patients: Explanations and Implications
The changing epidemiological changes among Far East and Southeast Asians and among Asian Americans in the USA are reviewed to determine whether these epidemiological shifts might have implications for the care of patients with HCC.
Changing epidemiology of hepatocellular carcinoma in Asia
HCC remains a major disease burden in Asia, and the management of HCC should be adjusted dynamically based on the changing epidemiology, as metabolic factors, including metabolic syndrome, obesity and non‐alcoholic fatty liver diseases, is increasing rapidly in Asia.
NCAPG is a prognostic biomarker associated with vascular invasion in hepatocellular carcinoma
Vascular invasion is closely associated with tumor recurrence and poor patient outcomes in individuals diagnosed with hepatocellular carcinoma (HCC); the potential value of NCAPG as a prognostic biomarker of vascular invasion in HCC patients is explored.
Hepatic Resection for Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease
After hepatic resection for hepatocellular carcinoma, NAFLD patients have better DFS and OS than patients with other risk factors and subgroup analysis and meta-regression suggested that the survival advantage of NAFLd patients was more pronounced in studies published after 2015 and from Asian centers.
Update on the Diagnosis and Treatment of Hepatocellular Carcinoma.
Data is reviewed on best practices for early detection and diagnosis of HCC and the current status of treatment options, which has been associated with increased survival.
Update in global trends and aetiology of hepatocellular carcinoma
This is a narrative review of findings of multiple studies that were retrieved from electronic databases like PubMed, MEDLINE, Embase, Google Scholar, Scopus, and Cochrane about the epidemiology and various risk factors for the development of HCC.
Current epidemiology in hepatocellular carcinoma
Interventions to minimize the global burden of HCC aim to reduce rates of the most common risk factors and implement effective treatment of underlying etiology and comprehensive screening programs for HCC.
Hepatocellular Carcinoma in Oman
The majority of Omani HCC patients were male and had cirrhosis due to viral hepatitis, and few patients were identified by the national surveillance programme and presented with advanced disease precluding therapeutic or even palliative treatment.
Single center analysis of therapy and outcomes of hepatocellular carcinoma in Sub-Saharan Africa
This study found that antiviral treatment of HBV infection was associated with longer survival in HCC and Sorafenib seemed beneficial in patients that used this modality and NLR was a good prognostic factor.
Treatment and the prognosis of hepatocellular carcinoma in Asia
  • T. Torimura, H. Iwamoto
  • Medicine, Biology
    Liver international : official journal of the International Association for the Study of the Liver
  • 2021
Intensive surveillance programmes and the development of radical and non‐radical treatments are indispensable for the improvement of prognosis in patients with hepatocellular carcinoma.


The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: A comprehensive and evidence‐based comparison and review
Hepatocellular carcinoma (HCC), the most common primary malignancy of the liver, represents 1 of the leading causes of cancer deaths in the world with an estimated 21,670 deaths in the United States
Clinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe
Differences between the aforementioned European and American clinical practice guidelines and Japaneseclinical practice guidelines will be discussed, as these guidelines primarily consist of both a surveillance and diagnostic algorithm and a treatment algorithm.
Asian Consensus Workshop Report: Expert Consensus Guideline for the Management of Intermediate and Advanced Hepatocellular Carcinoma in Asia
A new staging system representing prognoses suitable for Asian HCC patients and a corresponding optimal treatment algorithm should be further investigated using evidence-based data, which will finally bring about an Asian consensus for the management of intermediate and advanced stage HCC.
Hepatocellular carcinoma in the Asia pacific region
The importance of HCC may decrease in two to three decades when the prevalence of chronic HBV infection decreases as a result of the universal HBV vaccination programs implemented in late 1980s in most Asia‐Pacific countries, and because of reduced incidence of medical transmission of HCV.
Epidemiology and survival of hepatocellular carcinoma in north-east Peninsular Malaysia.
HCC in this study affected a wide age range, mostly male, in advanced stage of disease, with no treatment and very low survival rates, and primary prevention should be advocated in view of late presentation and difficulty of treatment.
Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort
The Barcelona Clinic Liver Cancer (BCLC) staging system had the best independent predictive power for survival when compared with the other 6 prognostic systems and provided the best prognostic stratification for this cohort of patients with HCC.
Hepatocellular Carcinoma: Trends of Incidence and Survival in Europe and the United States at the End of the 20th Century
Increasing incidence in southern Europe is probably related to hepatitis B and C infection and increasing alcohol intake, while improving survival may be due to greater surveillance for cirrhosis, and the survival gap between clinical and population-based series suggests management is better in centers of excellence.
Hong Kong Consensus Recommendations on the Management of Hepatocellular Carcinoma
Distinct from other regional guidelines, these recommendations provide guidance on the use of antiviral therapy to reduce the incidence of HCC in CHB patients with cirrhosis and to reduce recurrence of CHB-related HCC.
National Cancer Centre Singapore Consensus Guidelines for Hepatocellular Carcinoma
The NCCS Consensus Guidelines for HCC have been successfully implemented in the CLCC since their publication online on 26th September 2014, and the guidelines allow outcomes of treatment to be compared to international data and will be reviewed periodically to incorporate new data.
Epidemiology and survival of hepatocellular carcinoma in the central region of Thailand.
Surgical therapy or RFA seemed to provide better outcomes than other treatments but only in patients with early stage lesions, and Appropriate screening patients at risk for HCC might be an appropriate way to achieve early diagnosis and improve the treatment outcome.